Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

BioCryst Pharmaceuticals, Inc. (BCRX) vs Perrigo Company plc (PRGO)

BioCryst Pharmaceuticals, Inc. and Perrigo Company plc are both Drug Manufacturers Specialty & Generic companies. BioCryst Pharmaceuticals, Inc. and Perrigo Company plc are of similar size ($2.2B and $2.1B). BioCryst Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 68.7% against −4.19%. BioCryst Pharmaceuticals, Inc. has the higher net margin (−40.9% vs −41.9%) and the lower return on invested capital (−610.6% vs −18.1%). Both pay a dividend; BioCryst Pharmaceuticals, Inc. yields more (3.71% vs 3.42%). Across the 19 metrics below, BioCryst Pharmaceuticals, Inc. leads on 13 and Perrigo Company plc on 6.

Valuation

Metric BCRX PRGO Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 2.32 0.52 2.25
P/B n/m 0.85 1.90
Price to free cash flow 5.85 16.85 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 2.84 1.22 2.56
Earnings yield (16.76%) (81.06%) (2.99%)
Free cash flow yield 17.11% 5.93% 0.00%

Profitability

Metric BCRX PRGO Drug Manufacturers Specialty & Generic median
Gross margin 97.78% 33.26% 53.94%
Operating margin (33.29%) (37.71%) 0.00%
Net margin (40.90%) (41.85%) 0.00%
Free cash flow margin 39.75% 2.88% 0.00%
Return on equity 87.84% (49.65%) (0.40%)
Return on assets (75.79%) (19.60%) (3.32%)
Return on invested capital (610.55%) (18.06%) 0.00%

Growth

Metric BCRX PRGO Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 68.72% (4.19%) 10.01%
EPS growth (last fiscal year) 381.40% (723.20%) —
Revenue growth, 5-year CAGR 117.89% 0.79% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCRX PRGO Drug Manufacturers Specialty & Generic median
Debt to equity (1.85) 1.31 0.05
Current ratio 2.32 2.32 2.31
Net debt to EBITDA 0.61 (4.01) 0.85

Dividend

Metric BCRX PRGO Drug Manufacturers Specialty & Generic median
Dividend yield 3.71% 3.42% 1.70%
Payout ratio 0.00 — 0.00

Size

Metric BCRX PRGO Drug Manufacturers Specialty & Generic median
Market cap 2.18b 2.05b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack